- Home
- PYXS vs ACHV Comparison
PYXS vs ACHV Comparison
Compare PYXS & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PYXS | ACHV |
|---|---|---|
| Founded | 2018 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 243.5M | 239.0M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | PYXS | ACHV |
|---|---|---|
| Price | $1.11 | $4.49 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | $6.75 | ★ $15.50 |
| AVG Volume (30 Days) | ★ 1.7M | 501.6K |
| Earning Date | 11-03-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,820,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.83 | $1.84 |
| 52 Week High | $5.55 | $5.78 |
Technical Indicators
Market Signals| Indicator | PYXS | ACHV |
|---|---|---|
| Relative Strength Index (RSI) | 20.83 | 50.25 |
| Support Level | $1.05 | $4.25 |
| Resistance Level | $4.58 | $4.56 |
| Average True Range (ATR) | 0.30 | 0.22 |
| MACD | -0.36 | -0.02 |
| Stochastic Oscillator | 2.11 | 34.90 |
Price Performance
Historical ComparisonAbout PYXS Pyxis Oncology Inc.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.